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Abstract
Psychiatric disorders are among the most complex human disorders that, al-
beit often difficult to diagnose and treat, are widespread in modern society. 
Biological psychiatry studies biological functions of the central nervous system 
as mental disorders develop. Today’s biological psychiatry is facing multiple 
conceptual problems that prevent our deeper understanding of disease patho-
genesis and delay the invention of new treatments. Thus, providing a historical 
context to this rapidly developing field may help scientists better understand 
the existing challenges and their potential solutions. Here, we discuss the main 
conceptual problems and paradigms of biological psychiatry, including the lack 
of reproducibility and/or valid theories, through an historical overview of its 
role in addressing theoretical and clinical questions. We propose a wider use of 
the translational approach in psychiatry to expand our analyses of psychiatric 
disorders to other species, and as a tool to create and further develop theories 
and concepts in this field.
Keywords: biological psychiatry, translational medicine, history of psychiatry, 
modern psychiatry, conceptual issues in psychiatry.
Introduction
Psychiatric (mental) disorders are the most complex and frequently comorbid 
human disorders; they are becoming particularly widespread in modern society, 
but are difficult to properly characterize (Fears et al., 2014; Meyer-Lindenberg 
and Weinberger, 2006; Nestler and Hyman, 2010; Tsankova, Renthal, Kumar, and 
Nestler, 2007). Their polygenetic nature complicates genetic studies, which often 
yield not only disorder-specific genes but also multiple other candidate genes that 
are associated with other psychiatric disorders, thus showing significant overlaps 
(Cross-Disorder Group of the Psychiatric Genomics et al., 2013; Gaugler et al., 
2014; Ikeda et al., 2013; Ivleva et al., 2010; Murphy et al., 2003; Schizophrenia 
Working Group of the Psychiatric Genomics, 2014; Uddin et al., 2014). Further-
more, the low specificity, lack of personalization and slow pace of innovation in 
psychiatric practice collectively lead to inadequate treatment of mental diseases 
(Griebel and Holmes, 2013; McMahon and Insel, 2012). 
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Today, depression and other affective spectrum dis-
orders represent the leading causes of human disabil-
ity (Cryan and Mombereau, 2004; Murray and Lopez, 
1997). Despite the high prevalence and harm caused by 
both depressive and comorbid disorders, they remain 
poorly understood and are often treatment-resistant 
and recurrent (Cryan and Mombereau, 2004; Huynh 
and McIntyre, 2008; Insel and Charney, 2003; Schmidt, 
Wang, and Meijer, 2011; Wong and Licinio, 2004). 
As a field, biological psychiatry studies biological 
functions of the central nervous system (CNS) and de-
velopment of mental disorders. In a broad sense, this vi-
brant field represents a set of changing ideas, approaches 
and social practices aiming to describe and cure  deviant 
human behavior in terms of neurobiological discourse 
(D’haenen, den Boer, and Willner, 2002). To better un-
derstand the main conceptual problems that biological 
psychiatry faces today, and to find potential ways of their 
resolution, it is critical to first consider the historical 
perspective and main milestones in this field (Fig. 1). 
Milestones in biopsychiatric concepts
The science studying psychiatric disorders — psychia-
try — has a much longer history than neurology, which 
examines disorders with relatively clear and known neu-
ral pathology (Wickens, 2014). In fact, many currently 
recognized psychiatric conditions (e.g., mania, mel-
ancholy, and hysteria) were known in the time of Hip-
pocrates (Wickens, 2014), who in his Aphorisms noted 
that most of our feelings, if they are prolonged, should 
be considered symptoms of illness (Hippocrates, 2004). 
One of the first preserved notions of clinical depression 
is the 1500 BC Ebers Papyrus (Scholl, 2002). Notably, the 
term “melancholy” at that time was broader in meaning 
than it is now, and included not only low mood, despair 
and loss of energy, but also fear, aggression, obsessions 
and even hallucinations, thus incorporating depres-
sion, anxiety and psychotic disorders together (Radden, 
2003).
In early works, pathology of psychiatric disor-
ders was described as an imbalance of humors associ-
ated with relevant temperaments (Wickens, 2014) — the 
concept of humoralism in early psychiatry. This theory 
was based on 4  humors (blood, yellow bile, black bile 
and phlegm), the imbalance and “corruption” of which 
resulted in diseases and disabilities (Lindemann, 2010; 
Lloyd, 1983). It is possible that humoralism originated 
in Ancient Egypt or Mesopotamia (Sudhoff and Garri-
son, 1926; Van Sertima, 1992), but it was later adopted 
and developed by Hippocrates (Lloyd, 1983). A four-
temperament typology that linked imbalance of humors 
with temperaments was developed by Galen, who asso-
ciated each humor with the combination of 2 different 
qualities (hot/cold and dry/wet), jointly determining 
the respective temperament (sanguine, choleric, melan-
cholic and phlegmatic) (Boeree, 2014; Kagan, Snidman, 
Arcus, and Reznick, 1994). This influential concept was 
widely accepted and used by physicians and research-
ers, most notably by Avicenna (Lutz, 2002), and it was 
displaced only with the rise and development of modern 
theories of CNS pathology and cellular biology.
Before the “true” scientific study of mental dis-
orders began in the late 18th and 19th centuries, their 
“treatment” was characterized mostly by societal preju-
dices and punishments, as patients remained highly stig-
matized, despite some concern about mental health in 
times of Greek prosperity and their treatment with dif-
ferent holistic methods (Panksepp, 2004b, 2004c). While 
some humanistic positions existed in Middle Eastern 
countries, European countries remained in the Dark 
Ages for a long time, during which demonization of 
mental disorders dominated both society and medicine 
(Andreasen, 2004; Murad and Gordon, 2002; Panksepp, 
2004b; Stone, 1997). Indeed, many widely used biologi-
cal methods of therapy for mental disorders included 
drubbing, bleeding, starvation and temperature shock; 
they were based on prejudices rather than scientific ra-
tionale, and have since been recognized as ineffective 
Fig. 1. A brief history of biological psychiatry. It was already men-
tioned by Hippocrates that most of our feelings, if they are prolonged, 
should be considered symptoms of illness. Further development of 
psychiatry was the direct consequence of the growth of medical prac-
tice, resulting in pre-physiological hypotheses of mental disorders. 
Finally, contemporary psychiatry uses a wide variety of treatment 
methods and modern diagnostic tools.
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in modern practice (Panksepp, 2004b) (Fig. 2). Among 
the relatively effective methods used were placebo-and 
psychotherapy-like methods that involved witch doc-
tors, shamans and even skull trepanation for so-called 
“bad spirits extraction” (Panksepp, 2004b). Interest-
ingly, conceptually similar approaches, based on sympa-
thy/social concern and the placebo effect, are currently 
well known and are used in psychiatric practice with 
proven therapeutic effects (Harrington, 1999; Mayberg 
et al., 2002; Moerman, 2002; Panksepp, 2004a; Petrovic, 
Kalso, Petersson, and Ingvar, 2002; Shapiro and Shapiro, 
2000).
Certain views about somatic causes of mental dis-
orders, which are now fundamental in biological psy-
chiatry, could already be found in the 17th century. For 
example, Thomas Hobbes (1588–1679) suggested that 
motions of blood, animal spirits, “body parts” and or-
gans caused by phantasms concerning good and evil in 
the mind may lead to “madness” (Gert, 1996; Hobbes, 
1972; Hobbes and Macpherson, 1968). “Madness” was 
defined as excessive passions, the motion of which “may 
cause disturbances in different body parts” (Gert, 1996; 
Hobbes and Macpherson, 1968). Famous iatrochemist 
and early brain researcher Thomas Willis (1621–1675) 
also emphasized somatic causes of diseases and noted 
that brain function disturbances may lead to psychiat-
ric disorders, such as melancholia (Frank, 1980; Willis 
and Guidott, 1992). Willis also believed such changes to 
be potentially revealed by anatomical pathology meth-
ods like autopsy (Conry, 1978). Around the same time, 
Robert Burton (1577–1640) published The Anatomy of 
Melancholy, describing melancholic condition in detail, 
overviewing theories of its causes, expressing his own 
feelings and suggesting a healthy diet, proper sleep, mu-
sic, work and social communication as effective treat-
ment methods (Burton, 1931).
Nevertheless, the role of the nervous system in the 
function of a healthy individual as well as in the prog-
ress of pathological conditions was not actively studied 
until the 18th century (Wickens, 2014). Around that 
time, CNS disorders became especially recognized by 
the rapidly growing medical practice (Wickens, 2014). 
The existence of clear organic bases for neurological 
diseases provided neurological methods that were not 
accessible for psychiatry, and in this way neurological 
studies built the foundation for further development 
of psychiatry (Panksepp, 2004b; Wickens, 2014). For 
example, case history review or autopsy were used by 
Giovanni-Battista Morgagni (1682–1771)  and further 
applied in neurology by Jean-Martin Charcot (1825–
1893), facilitating the relatively fast growth of neurology 
in the 18–19th centuries (Wickens, 2014). Interestingly, 
as a result of his postmortem studies of psychiatric pa-
tients, Morgagni emphasized the lack of reproducibility 
of others researchers’ results (Bonet, 1700; Morgagni, 
1769), also noting that the same diseases may show le-
sions in different parts of the brain (Morgagni, 1769). 
However, further development of ideas about the role of 
the brain in human life continued. For example, Pierre 
Cabanis (1757–1808) suggested that the brain “excretes” 
thoughts and this may create complex conscious and 
mental disorders (Cabanis and Cerise, 1843). 
Fig. 2. Evolution of selected commonly used psychiatric treatment methods. The size of each phase 
displays treatment capacity of methods used at particular time. The color reflects the relative safe-
ty of implemented treatments, from safe (green) to unsafe (red).
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In the meanwhile, studying psychiatric disorders 
required other approaches, given the lack of pronounced 
organic lesions and the wide diversity that complicates 
classification (Wickens, 2014). The 19th century (espe-
cially the 1850–1900s) is often called the beginning of 
true thorough and systematic studies of mental disorders 
(Panksepp, 2004b). This period started with the works of 
Benjamin Rush (1745–1813) in the USA, Philippe Pinel 
(1745–1826) in France and Vincenzo Chiarugi (1759–
1820) in Italy, who laid the foundation of “moral treat-
ment” of patients (Panksepp, 2004b). Specifically, they 
helped establish the practice of asylums for psychiatric 
patients in small humanistic hospitals, in which thera-
peutic space was created to recover patients’ emotional 
homeostasis (Panksepp, 2004b). Besides “psychological” 
treatment, some auxiliary “somatic” methods, such as 
bloodletting, induced vomiting, diets, physical restraint 
and electroconvulsive shock, were used, but collectively 
fell into decline by the 20th century (Panksepp, 2004b).
Etienne-Jean Georget (1795–1828), based on Ma-
rie F. X. Bichat’s (1771–1802) ideas of vitalism, suggested 
that mental disorders have an organic nature and intro-
duced the term “technology alibi”, which plays a criti-
cal role in today’s biopsychiatry (Berrios and Marková, 
2002; Georget, 1820). The technology alibi is a funda-
mental assumption of psychiatry that is based on syllo-
gism: the mind is represented in the brain — the mind is 
tantamount to a set of behaviors — hence, all behaviors 
are represented in the brain — abnormal behaviors are 
still behaviors — hence, all behaviors have brain repre-
sentation — thus, the fact that no brain representation 
can yet be found for mental disorders must be due to 
faulty techniques (Berrios and Marková, 2002). In this 
way, the technology alibi plays a large role in biological 
psychiatry, providing it freedom to investigate psychiat-
ric diseases as brain diseases without rigorous proof of 
this claim.
Similarly, Wilhelm Griesinger (1817–1868) viewed 
all mental diseases as brain diseases, and considered 
brain lesions as a physiological, not anatomical con-
cept (Berrios and Marková, 2002). However, although 
Griesinger called mental disorders organic or biological 
in nature, he did not presume that these disorders must 
have a reflection in the brain, so his views on physio-
logical lesions were closer to psychological trauma (Por-
ter, 1988). He also noted that official clinical categories 
would always be arbitrary, whereas “elementary” ana-
lytical units (symptoms) are ontologically stable (Ber-
rios, 1996). Theodor Hermann Meynert (1833–1892) 
described pathological conditions as changes in brain 
blood supply, and the main causal mechanism  — as 
changes in cellular nutrition caused by these blood 
supply disruptions and birth defects (Berrios and Mar-
ková, 2002; Meynert, 1885). Interestingly, Carl Lange’s 
(1834–1900) theory of emotion was proposed in almost 
the same period, and is also linked blood circulation, va-
soconstriction, perfusion and nutrition to pathological 
affective conditions (Wassmann, 2010).
A seminal step in the study of psychiatric disorders 
was made by Emil Kraepelin (1856–1926), often called 
the father of modern psychiatry (Panksepp, 2004b; 
Wickens, 2014). Kraepelin first described “dementia 
praecox”, which is now widely known as schizophrenia, 
and created a dichotomic classification of psychiatric 
disorders into neuroses and psychoses, which has influ-
enced many others classifications and theories that now 
are widely used by health organizations (Wickens, 2014). 
Notably, Kraepelin’s classification was largely influenced 
by Karl Ludwig Kahlbaum (1828–1899) and his protégé 
Ewald Hecker (1843–1909) (Berrios, 1996; Berrios and 
Hauser, 1988; Kendler and Engstrom, 2016; Kraepelin, 
1905; Kraepelin, 1983), who paid special attention to 
criticizing the imperfection of 19th-century psychiatric 
systematics (Kendler and Engstrom, 2016). For example, 
they noted that this systematics consisted of the symp-
tom complexes, but not the diseases, and recognized that 
their high heterogeneity complicates understanding of 
the etiology, the prognosis of course of the diseases and 
their treatment (Kahlbaum, 1863; Kahlbaum and Ber-
rios, 1996; Kendler and Engstrom, 2016; Kraam, 2004). 
In response, they suggested a new method of detailed 
and empirical observations, in which special attention 
should be paid to broad temporal spectra of disease pro-
gression in patients (Kendler and Engstrom, 2016). They 
identified and described such conditions as hebephre-
nia, catatonia and cyclic madness (Baethge, Salvatore, 
and Baldessarini, 2003; Hecker and Kraam, 2009; Kahl-
baum, 1973; Kendler and Engstrom, 2016), which were 
further conceptually developed by Kraepelin (Kendler 
and Engstrom, 2016).
Kraepelin’s main work, Textbook of Psychiatry, 
played a major role in the development of biological psy-
chiatry (Wickens, 2014). In Kraepelin’s time, psychiatric 
disorders were typically diagnosed by the main, most 
pronounced symptom (e.g., melancholia or madness) 
which was typically caused by a trauma, such as loss of 
a friend (Wickens, 2014). Subsequently, Kraepelin made 
several important observations. For example, comparing 
the speed of disease progression, he concluded that all 
diseases can be split into “curable” or “incurable” based 
on their progression speed (Wickens, 2014). Studying 
patients with different early clinical representations that 
later progressed into senile dementia, he found that these 
conditions can be described as united, called it demen-
tia praecox, and distinguished it in it such subtypes as 
regular, paranoid, catatonic and hebephrenic (Wickens, 
2014). Furthermore, Kraepelin was the first to split psy-
chosis (then viewed as a disjointed cluster of diseases 
with unclear organic causes) into manic depression and 
dementia praecox (Wickens, 2014). At the same time, 
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manic depression itself consisted of all affective spectrum 
pathologies and was split into externally and internally 
caused disorders (Davison, 2006). Interestingly, Krae-
pelin thought that dementia praecox was an incurable 
disease, in contrast to depression, which is relatively cur-
able and temporal (Wickens, 2014). In contrast, Eugen 
Bleuler (1857–1939) suggested that dementia praecox 
could not be an incurable condition since he could see 
significant improvement in many patients, and argued 
that this condition is determined through disorganized 
thinking caused by the split of emotional and intellectual 
functions (Wickens, 2014). The term “schizophrenia” was 
chosen for this condition, and its main symptoms were 
recognized as reduced emotional response, weakened as-
sociations, indifference or inability to make choices, and 
autism (at that time the term was used to describe con-
centration on a person’s own thoughts) (Wickens, 2014). 
Also, Bleuler noticed that symptoms of schizophrenia 
can be grouped into positive (e.g., excess activity and 
thinking) and negative (e.g., reduced or impaired/insuf-
ficient activity and thinking) (Wickens, 2014). 
Another important opponent of Kraepelin was Carl 
Wernicke (1848–1905), deservingly considered one 
of the most important psychiatrists of the 19th century 
(Lanczik, 1988). One of Wernicke’s key findings was the 
creation of the first CNS model that reflected the con-
nection between different areas of the brain and specific 
behaviors. This thought was the first of its kind, and 
highly suitable for direct pathophysiological studies; it 
was the first example of a model that used a neuropsy-
chological approach for psychiatric disorders (Berrios 
and Marková, 2002). Interestingly, his model was based 
on Meynert’s ideas that the brain is filled by projections 
and associative fibers, in which conscious is based (Ber-
rios and Marková, 2002; Wernicke, 1906). Thus, projec-
tion lesions lead to neurological diseases, and lesions of 
the associative system — to psychiatric disorders (Ber-
rios and Marková, 2002; Stein and Ludik, 1998).
In Kraepelin’s time, there already were established 
psychopharmacological practices (Preston, O’Neal, and 
Talaga, 2010). For example, Kraepelin himself often 
used opium, morphine, scopolamine and hashish for 
stimulation, whereas to induce sleep he used chloral hy-
drate, ether, alcohol, chloroform and bromides (Spiegel, 
2003). However, Kraepelin noticed that none of these 
drugs could treat psychiatric disorders, their use was 
rather short-term, and some of them could cause addic-
tion (Preston et al., 2010). As other authors reported, the 
use of these drugs can help to gain control over a patient 
by sedation, but cannot treat psychotic symptoms per se 
(Preston et al., 2010).
Important, but rather underappreciated, is the con-
tribution to biological psychiatry made by Constantin 
von Monakow (1853–1930) and Raoul Mourgue (1886–
1950) (Berrios and Marková, 2002; von Monakow and 
Mourgue, 1928), who pointed out that neuropsychiatric 
phenomena and functions should be viewed as insepa-
rable from the function of time, making an analogy to a 
process of movement (Berrios and Marková, 2002). Ac-
cording to these views, it may not be correct to associate 
these processes with specific brain areas in isolation from 
a change in location of such processes with time (Berrios 
and Marková, 2002). Indeed, the brain processes infor-
mation in different areas in complicated patterns, and 
these diverse parts need to constantly coordinate their 
functions. Expanding this idea, a psychiatric disorder 
can be seen as a consequence of time–function distur-
bance, and should be viewed with the use of the time 
concept (Berrios and Marková, 2002). Thus, Monakov 
and Mourge’s theory of chronogenic localization was 
one of the first dynamic models in biological psychiatry.
Adolf Mayer (1866–1950) actively promoted a ho-
listic (“whole self ”) approach to psychiatric treatment in 
the late 19th — early 20th centuries (Panksepp, 2004b). 
For example, he actively used thorough documenta-
tion of patients’ lives; he also rightly emphasized the 
importance of both psychological and biological effects 
that may impact the patient for effective treatment, and 
the uniqueness of each individual’s traits and, conse-
quently, their treatment (Panksepp, 2004b). Mayer’s ap-
proach was key for pioneers in the field of studying ani-
mals’ self-regulation, such as Kurt Richter (1894–1988) 
with his study of appetite, sleep and circadian rhythms 
(McHugh and Slavney, 1998). Mayer’s views about indi-
viduality, including his belief that a person’s strong and 
weak sides ought to be taken into account in treatment, 
have further developed and can be seen today in genet-
ic approaches and personalized medicine in treatment 
practice (Panksepp, 2004b). In the context of depression, 
Mayer noted the importance of the interaction of social 
and biological factors, which mediates individual reac-
tions, and he especially emphasized his preference for 
the term “depression” rather than “melancholy” (Lewis, 
1934).
The second half of the 19th century raised other 
spectrum ideas that were closely related to psychiatry. 
For example, Sigmund Freud’s (1856–1939) theory of 
psychoanalysis and psychodynamic approach revolu-
tionized our view of the mind by the popularization of 
the idea of the unconscious (Panksepp, 2004b). After a 
slump in interest in Meyer’s concept in the 1940s, psy-
chological theories of Viktor Emil Frankl (1905–1997), 
Albert Ellis (1913–2007), Aaron Beck (born 1921), Freud 
and others, became influential and widely recognized 
(Beck, 1979; Blair, 2004; Carhart-Harris et al., 2014; El-
lis, 1962; Frankl, 1976; Freud, 1984; Radden, 2003; Se-
idner, 2009). However, the lack of rigorous scientific ar-
gumentation, along with the success of pharmaceutical 
therapy of psychiatric disorders, led to justified criticism 
of Freud’s theories in the late 20th century. Nevertheless, 
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these theories continue to be further developed in mod-
ern time and have gained improved scientific basis by 
neuropsychoanalytic methods (Panksepp, 2004b; Solms 
and Turnbull, 2002). 
During this period, there were still multiple ma-
nipulations that are now considered radical, such as 
metrazole- or insulin-induced seizures, electroconvul-
sive therapy and lobotomy (Panksepp, 2004b; Valen-
stein, 1974). Widespread use of psychosurgery helped 
to effectively stabilize agitated psychotic patients, but 
it was done at a high human cost, since lobotomized 
patients often became unenergetic, passive and “emo-
tionally dead” (Preston et al., 2010). Electroconvulsive 
treatment, on the other hand, could have a good effect 
on some patients (Preston et al., 2010). However, its use 
was far from perfect and often led to strong side effects. 
Furthermore, it was widespread and prescribed inap-
propriately, often ignoring the lack of positive response 
in some groups of patients (Preston et al., 2010). How-
ever, the most affected patients continued to be kept in 
overcrowded hospitals and “treated” with such crude 
methods as isolation and restraint, due to the absence 
of other, more effective therapies (Preston et al., 2010).
The next period in biological psychiatry, which is 
often called psychopharmacological, started with the 
discovery of highly efficient chlorpromazine by Jean 
Delay (1907–1987) and Pierre Deniker (1917–1998), 
and lithium drugs by John Cade (1912–1980) in the late 
1940s — early 1950s (Cade, 2000; López-Muñoz et al., 
2005; Panksepp, 2004b). These findings led to an ava-
lanche of psychopharmacological discoveries. For ex-
ample, Paul Janssen (1926–2003), based on the knowl-
edge that chlorpromazine-like drugs cause their effects 
primarily through the dopaminergic system, created 
haloperidol and risperidone — the ancestors of today’s 
atypical antipsychotics (Panksepp, 2004b). 
Around the same time, the first drugs with anti-
depressant activity were discovered, as Delay and Max 
Lurie tested an antitubercular drug, isoniazid (which 
also caused a stimulating effect in patients), and found 
improvement in depressed patients after treatment with 
the drug (Ayd and Healy, 1996; Healy, 2001; Selikoff and 
Robitzek, 1952). The effect of iproniazid was discovered 
in the same way (López-Munoz, Alamo, Juckel, and 
Assion, 2007; Robitzek, Selikoff, Mamlok, and Tend-
lau, 1953). The antidepressant effect of these two drugs 
is related to their inhibition of monoamine oxidase A 
(MAO-A) (López-Munoz et al., 2007). Additionally, 
Roland Khun (1912–2005) presented the first tricyclic 
antidepressant, imipramine, following an attempt to im-
prove chlorpromazine action (Kuhn, 1958). As a result of 
translational research of the 1960s, benzodiazepines — 
anxiolytic drugs that cause sedative and antiagressive ef-
fects, such as chlordiazepoxide — were also introduced 
(Panksepp, 2004b). In the USSR, Svyatoslav Lapin and 
Grigory Oxenkrug put forth the serotonergic theory of 
depression (Lapin and Oxenkrug, 1969), which subse-
quently led to the discovery of selective serotonin reup-
take inhibitors (SSRIs) — currently, the most prescribed 
(Coupland et al., 2015) and one of the most efficient an-
tidepressant medications today (Cuijpers, van Straten, 
van Oppen, and Andersson, 2008).
Clinical success of psychopharmacological drugs 
and the development of neurochemical synaptic trans-
mission theory dramatically accelerated the descrip-
tion of the main neurochemical brain systems and the 
growth of preclinical psychopharmacology (Charney, 
Buxbaum, Sklar, and Nestler, 2013; D’haenen et al., 
2002; Panksepp, 2004b; Preston et al., 2010). Conse-
quently, powerful behavioral analysis and psychoactive 
drug screening methods were created. In such studies, 
animals were essentially used as “biological computers” 
in which drugs with potential psychoactive effect were 
placed, and behavioral reactions were collected as out-
put information reflecting the effect of the drug. How-
ever, excessive focus on such methods led to a relatively 
slow pace of psychobehavioral systems’ analyses (Pank-
sepp, 2004b), thus necessitating further development of 
methodology and theories in this field. 
With the advent of genetics, the focus of biological 
psychiatry began to shift to identifying family patterns 
in psychiatric disorders. As these studies shed light on 
a high genetic load of some psychiatric disorders, find-
ing the genetic component of other diseases proved to 
be complicated (Preston et al., 2010). Recent advantages 
in biotechnology have made it possible to systemati-
cally test single nucleotide polymorphisms or large copy 
number variants by genome-wide association studies 
(GWAS) (Wray et al., 2014). Today, various copy num-
ber variants are found for shizophrenia, autism, bipolar 
and major depressive disorders (Lee and Avramopoulos, 
2014). Other approaches that are relatively effective and 
widely used in translational psychiatry include disease-
specific differential gene expression studies. Unfortu-
nately, both approaches consistently reveal significant 
overlaps and shared molecular pathways across psychi-
atric disorders (Cross-Disorder Group of the Psychiat-
ric Genomics, 2013; Gandal et al., 2018). Furthermore, 
although some disorders show high heritability, for the 
vast majority of cases, their genetic etiology remains un-
clear, meriting further scrutiny (Lee and Avramopoulos, 
2014).
While psychiatric genetics countinues to grow with 
improvements in experimental and analytical methods, 
the field of psychiatric epigenetics has also begun to gain 
momentum (Lee and Avramopoulos, 2014). Epigenetics 
refers to processes that alter gene expression without 
changes in DNA sequence, primarily through DNA 
methylation and changes in histone structure (Roach, 
Bronner, and Oreffo, 2011). Multiple studies have shown 
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the role of epigenetics mechanisms in different aspects of 
psychiatrc disorders (Peedicayil, Grayson, and Avramo-
poulos, 2014; Yasui, Peedicayil, and Grayson, 2016), al-
though it remains unclear how exactly epigenetic factors 
contribute to the pathophysiology of specific mental dis-
orders (Kato, 2009).
In parallel, the first international classifications of 
mental disorders were created, thereby continuing Krae-
pelin’s work (APA, 1960) and putting forth novel dis-
order constructs and theories. For example, depression 
pathogenesis theories developed then primarily viewed 
the disorder as a neurochemical imbalance (Schildkraut, 
1965), and were based on robust antidepressant effects 
that continue to play an important role in today’s scien-
tific discussions and antidepressant development. 
Finally, modern biological psychiatry is a skyrock-
eting field powerfully enriched by many new effective 
methods and tools (Fig. 3). For instance, neuroimaging 
has emerged as a valuable tool that allows researchers to 
investigate brain structures and activity of humans and 
animals in vivo (Linden, 2012; Misgeld and Kerschen-
steiner, 2006). These techniques include computerized 
tomography (CT) and magnetic resonance imaging 
(MRI), functional magnetic resonance imaging (fMRI), 
positron emission tomography (PET), single photon 
emission computerized tomography (SPECT), near-
infrared spectroscopy (NIRS), magnetoencephalogra-
phy (MEG) and electroencephalography (EEG)/event-
related potentials (ERP) (Linden and Fallgatter, 2009). 
Developing early neuromorphological works of Ramon 
y Cajal (1852–1934) (Finger, 2000) and Alois Alzheimer 
(1864–1915) (Berrios, 1990), modern neuroimaging 
studies in psychiatry picked up in 1976 with the finding 
of enlarged cerebral ventricles in schizophrenics (John-
stone, Crow, Frith, Husband, and Kreel, 1976). Neuro-
imaging can potentially be used to find biomarkers of 
disease, prognosis or treatment; investigate biological 
pathways; and help redefine diagnostic boundaries and 
monitor new therapies (Linden, 2012). Unfortunately, 
although some imaging and electrophysiological pheno-
types are associated with mental disorders, none of them 
are currently valid as a diagnostic marker (Linden, 2012). 
Nevertheless, these techniques create a productive basis 
for brain functional mapping and connectomics stud-
ies. These connectome-based approaches present new 
opportunities in studies of psychiatric diseases, and the 
identified disrupted networks may potentially represent 
valuable biomarkers of psychiatric disorders such as de-
pression (Gong and He, 2015). 
Another extremely effective recent research tool in 
biological psychiatry is optogenetics — a method which 
enables precise control of the activity of neuronal clus-
Fig. 3. The diversity of common methods used in contemporary research in biological psychiatry 
research, and their potential implementation.
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ters and has become an effective tool in both neural cir-
cuits and behavioral studies (Chen, Zeng, and Hu, 2012; 
Francis, Chaudhury, and Lobo, 2014; Hegemann and 
Sigrist, 2013; Yizhar, Fenno, Davidson, Mogri, and De-
isseroth, 2011; Zeng and Madisen, 2012). Optogenetic 
methods have now enabled acquisition of insights into a 
broad range of questions in behavior, physiology and pa-
thology, spanning domains of sensation, cognition, and 
action (Deisseroth, 2015). Comprehensively discussed 
recently (Deisseroth, 2015), these methods continue to 
contribute to modern biological psychiatry.
Complementary and alternative medicine (CAM) 
in psychiatry is an integrative approach combining dif-
ferent treatment techniques that concentrate on lifestyle 
changes, relatively low-invasive natural drugs and tra-
ditional medicine practices. These techniques include 
such treatments as exercise, sleep, nutrition, stress man-
agement, light therapy, St. John’s Wort (SJW), S-adeno-
sylmethionine (SAMe), yoga, meditation, acupuncture 
and a variety of spiritual practices (Muskin, 2008; Vora, 
Aloysi, and Zhuk, 2017). Use of these techniques is es-
pecially promising in the treatment of depression, and 
inclusion of integrative approach treatments based on 
management and light treatment is highly recommend-
ed in both treatment-resistant and recurrent cases (Vora 
et al., 2017). SJW and SAMe are among the few well 
studied CAM drugs and may be considered as treatment 
medication for some patients (Vora et al., 2017). 
From a data analysis standpoint, the use of big data 
grants unparalleled opportunities to investigate different 
scientific problems. Today, numerous modern technolo-
gies, including mobile technologies, social media and 
internet, can be used to quickly collect and analyze big 
data from a large number of patients. These practices 
have already proved to be effective (Swendsen and Sal-
amon, 2012), although they raise various practical and 
ethical questions, ranging from psychiatrist–patient per-
sonal boundaries violation and the ethics of high-scale 
medical data monitoring (Andlauer, Lydall, Nawka, and 
Guloksuz, 2015). As these challenges complicate the use 
of modern technologies by some psychiatrists (Andlauer 
et al., 2015), digital healthcare data being collected at an 
incredible speed, at a rate of about 50% per year (Monte-
ith, Glenn, Geddes, and Bauer, 2015). Thus, there is hope 
that the growing use of big data in psychiatry will pro-
vide opportunities for exploration, descriptive observa-
tion, hypothesis generation, and prediction for clinical, 
research and business issues (Monteith et al., 2015). In-
deed, there have already been some promising findings 
in the following areas: suicide, substance abuse, bipolar 
disorder, safety of antipsychotic medications, depression 
management and screening, association of head injuries 
with psychiatric disorders, the use of natural language 
processing to identify treatment-resistant depression 
and the risk of autism (Castro et al., 2015; Grether, An-
derson, Croen, Smith, and Windham, 2009; Huybrechts 
et al., 2012; Kessler et al., 2015; Orlovska et al., 2014; Per-
lis et al., 2012; Valuck et al., 2012; Wu et al., 2013). An-
other interesting potential use of big data in psychiatry is 
finding behavioral traits that were previously difficult or 
impossible to detect (Monteith et al., 2015). 
A good combination of big data with machine 
learning approaches can also help achieve some goals 
of personalized medicine, since it should provide high 
quality treatment prediction for individual cases (Gillan 
and Whelan, 2017). Personalized medicine, as a concept, 
was developed a long time ago, first introduced by Hip-
pocrates and not undergone many changes since (Abra-
hams and Silver, 2010). However, what has changed is 
the rapid growth of sophisticated methods, theories and 
an overall understanding of how we should apply these 
theories to treat individual diseases. Thus, modern per-
sonalized medicine is concentrating on finding ways to 
successfully and most effectively treat each patient based 
on the knowledge of internal and external factors sug-
gested to be involved in pathogenesis (Emmert-Streib, 
2013). Personalized psychiatry looks especially promis-
ing since psychiatric patients tend to exhibit significant 
inter-individual variability in their responses to psycho-
active drugs (Costa e Silva, 2013). Unfortunately, the 
field is still mostly in the information-gathering stage, 
and a deeper understanding of biomarkers, genes and 
environmental factors is therefore needed to develop 
truly personalized psychiatric approaches (Ozomaro, 
Wahlestedt, and Nemeroff, 2013).
The modern term “holistic psychiatry” is usu-
ally described as the “whole self ” approach, including 
mind and body concepts (Wallace, 2008), an increased 
humanistic aspect in treatment of psychiatric diseases 
(Linnett, 2006), a systemic (organizational/integrative) 
view on human behavior (Angyal, 1948) and question-
ing of our understanding self and identity in a psychi-
atric context (Crossley, 2012). All of these holistic cat-
egories represent the whole-person care approach that 
is highly desired yet remains hard to reach for biological 
psychiatry. It is also worth noting that the role of other 
physiological systems in psychiatric disorders, such as 
the endocrine, gastrointestinal, immune, and other sys-
tems, is beginning to receive increased attention (Ma et 
al., 2017). 
Sex and gender differences are also experiencing re-
surged interest in current psychiatric practice. Although 
physicians have been trying to understand the biologi-
cal differences between men and women for centuries, 
they continue to face challenges in the context of sex-
specific psychiatric diseases. Furthermore, our previous 
views on such differences were quite sexist and highly 
based on cultural understanding of gender roles in the 
past. For instance, maleness has traditionally been seen 
as superior to femaleness, and some psychiatric diagno-
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ses (e.g., hysteria and borderline personality disorder) 
were “reserved” for females (Nissim-Sabat, 2013). For 
today’s gender psychiatry, the main challenge is to un-
tangle social and cultural factors from biological (Hirsh-
bein, 2010). Understanding the sex impact on psychi-
atric disease predisposition and progression may help 
to increase effectiveness of treatment and make it more 
personalized.
Discussion
In conclusion, the need for new methods of treatment 
necessitates further development of current CNS patho-
genesis theories of brain disorders which could explain 
how exactly psychiatric disorders emerge, how psycho-
logical and biological processes develop, and how these 
disorders relate to treatments. Especially promising here 
is the approach of translational biopsychiatry, which 
provides a unique, evolution-based vision of psychiatric 
diseases. However, there are major problems which bio-
psychiatry is facing. For example, the field needs novel 
sensitive biomarkers of psychiatric disorders, especially 
for its early/presymptomatic progression (Panksepp, 
2004b). Another problem, already discussed here, is the 
need for new classification systems of psychiatric disor-
ders. Many established disease classifications have been 
justly criticized for a long time for low accuracy, diag-
nostic heterogeneity, high comorbidity, troubled use and 
blurred categories (Aragona, 2009b; Baca-Garcia et al., 
2007; Kendell and Jablensky, 2003; Pincus, Zarin, and 
First, 1998). Thus, a new taxonomical system may re-
quire a radical rethinking of psychiatric disorders, prob-
ably in terms of neurobiological discourse (Aragona, 
2009a; Tadafumi Kato, 2011).
Works dedicated to this problem began to appear in 
the 1970s. For example, Irving Gottesman (1930–2016) 
Fig. 4. Endophenotype- and domain-based therapy strategies in biological psychiatry. Human brain 
diseases may be deconstructed into smaller units — major psychiatric domains (e.g., affect, cogni-
tion, activity) — which can be further deconstructed into endophenotypes. As genes’ activity modu-
lates behavioral patterns, their interaction leads to a particular endophenotype which results in 
specific behavioral patterns. Thus, correction of a particular gene’s activity may help correct endo-
phenotypes and, eventually, cure the disease that contains this aberrant endophenotype.
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coined the term “endophenotype” (Fig. 4) and aimed to 
reconstruct gene–behavior associations by deconstruct-
ing complex disorder systems into small blocks (Got-
tesman and Gould, 2003; Gould and Gottesman, 2006). 
Endophenotypes are objective, biological or behavioral 
signs of disorders which exist in an organism regardless 
of the presence or absence of the disorder, and can be 
found in a patient’s relatives that were not affected by the 
disease in higher levels than the average population level 
(Cannon and Keller, 2006; LaPorte et al., 2010). In the 
last decades, the concept of endophenotype has become 
widely accepted and is one of the most influential in bio-
logical psychiatry (Braff, 2015; Cannon and Keller, 2006; 
Flint and Munafo, 2014; Glahn et al., 2012; Glahn et al., 
2014; Hasler, Drevets, Gould, Gottesman, and Manji, 
2006). However, even this concept alone could not solve 
the problems of the spectrum nature of psychiatric dis-
eases and cross-linking of genetic determinates, molec-
ular pathways, and symptoms (Kalueff, Ren-Patterson, 
LaPorte, and Murphy, 2008; Kalueff and Stewart, 2015). 
One of the recent outcomes of the endophenotype 
concept was the cross-species trait genetics approach 
(Kas, Fernandes, Schalkwyk, and Collier, 2007). This 
approach is based on the idea that behaviors should be 
conserved in genetic variance across species due to their 
involvement in common survival mechanisms that al-
low adaptation to an ever-changing environment. This 
concept suggests that genotype–phenotype relationships 
exist between animals and humans in terms of traits 
(Kas et al., 2007).
Another important concept was developed by the 
US National Institute of Mental Health (NIMH) as a Re-
search Domain Criteria (RDoC) project (https://www.
nimh.nih.gov/research-priorities/rdoc/ (Cuthbert and 
Insel, 2010; Insel et al., 2010)) to facilitate the transla-
tion of modern molecular biology, neuroscience and 
behavioral approaches in an attempt to better explain 
the physiology of mental disorders (Ceusters, Jensen, 
and Diehl, 2017). The concept has created a matrix in 
which “constructs” (representing aspects of behavior) 
are related to “elements”/“units of analysis” (represent-
ing primarily biomarkers). Constructs are further com-
bined into psychiatric domains; currently 5 psychiatric 
domains are described: Negative or Positive Valence 
Systems, Cognitive Systems, Social Processes, Arousal 
and Regulatory Systems, and an additional 6th Motor 
Systems Domain is currently under debate (Garvey and 
Cuthbert, 2017). Currently, this trans-diagnostic ap-
proach is actively collecting data for further investiga-
tions. Such trans-diagnostic, cross-domain/cross-dis-
order approaches in psychiatry are receiving increasing 
attention and are markedly improving our understand 
of comorbidity, cross-disorder biomarkers and patholo-
gies (Harvey, 2004). 
Conclusion
From the brief historical perspective provided here, one 
can see that the current problems of biological psychia-
try are still the same as they were at its start. Today, like 
centuries ago, the field still faces the lack of reproduc-
ibility; problems with systematization, proper terms and 
understanding of psychiatric disorders core domains; 
as well as the lack of humanistic approaches. The field, 
though rapidly progressing, still lacks connection be-
tween psychology and psychiatry, between biology and 
psychology, between data and valid theories. The lack of 
disorder progress trajectory-based approaches and the 
technology alibi still serve as crutches for psychiatric 
theoretical constructs. To address such problems, a wider 
use of translational approaches in psychiatry is urgently 
needed, representing a unique tool to study evolutional 
conservative traits of disorders pathogenesis. If success-
ful, such an expansion of views on psychiatric disorders 
may provide a powerful base for new theories and could 
help create fundamentally new concepts of conscious-
ness and mind across a wide spectrum of organisms.
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